Bryan E. Smith
CIK: 0001748041
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Eledon Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jan 10, 2025ELDN
Eledon Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
150.5K shares- - Jan 10, 2025ELDN
Eledon Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
64.5K shares- - Nov 21, 2024ELDN
Eledon Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
474.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 10, 2025 | ELDN Eledon Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 150,500 | - | - | Direct |
| Jan 10, 2025 | ELDN Eledon Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 64,500 | - | - | Direct |
| Nov 21, 2024 | ELDN Eledon Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 474,350 | - | - | Direct |
1-3 of 3 transactions
About Smith Bryan E.
Smith Bryan E. (SEC CIK 0001748041) files insider reports with the SEC as General Counsel, Corporate Sec of Eledon Pharmaceuticals, Inc. (ELDN).
Signal8 holds 2 ownership filings by Smith Bryan E., all Form 4s, filed between Nov 22, 2024 and Jan 13, 2025. Those filings report 3 transactions, from Nov 21, 2024 to Jan 10, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith Bryan E.'s filings is in IRVINE, CA.
Recent filings by Smith Bryan E.
Other insiders filing for Eledon Pharmaceuticals, Inc. (ELDN)
- Gros David-Alexandre C, Chief Executive Officer
- Perrin Steven, President
- McBride John S., Director
- Hillson Jan, Director
- Kirk Allan, Director
- Katkin Keith, Director